Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zymeworks ( (ZYME) ) has shared an announcement.
Zymeworks announced a broad reshaping of its governance and executive ranks to better align with its recently updated corporate strategy, highlighting both board-level and operational changes aimed at supporting its next phase of growth. The company added investment industry veteran Brian Cherry to its board, the fourth new director in a year, as it trims the board from 12 to nine members and sharpens its focus on capital allocation and strategic transactions. Internally, Zymeworks promoted Mark Hollywood to Executive Vice President and Chief Operating Officer, elevated Sabeen Mekan to Chief Medical Officer effective February 2026 following the planned retirement of current CMO Jeff Smith, and began a search for a new Chief Financial Officer after the planned departures of Chief Financial and Business Officer Leone Patterson and General Counsel Daniel Dex. In tandem, the company filled several senior and vice president roles across human resources, finance, corporate development, translational sciences, investor relations, communications, treasury and tax, and regulatory affairs, underscoring its intent to build a more experienced and specialized leadership bench to execute its strategy and support long-term growth.
The most recent analyst rating on (ZYME) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
The score is held back mainly by weak profitability and negative operating cash flow, with additional pressure from bearish/oversold technical signals. Offsetting these, the latest earnings call was meaningfully constructive—highlighting milestone-driven revenue growth, promising clinical updates, and a multi-year cash runway—supporting a more neutral overall outcome.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc., headquartered in Vancouver and listed on Nasdaq under the ticker ZYME, is a biotechnology company that manages a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics. The company focuses on advancing innovative therapies across its portfolio and emphasizes internal leadership development to support disciplined execution of its corporate strategy and long-term shareholder value creation.
Average Trading Volume: 1,207,238
Technical Sentiment Signal: Buy
Current Market Cap: $1.74B
See more data about ZYME stock on TipRanks’ Stock Analysis page.